Sector News

Bluebird, with little fanfare, is first to bring a second gene therapy to market

July 25, 2021
Life sciences

Bluebird is an important company in gene therapy’s reemergence. The company’s progress developing treatments for rare genetic diseases early last decade helped boost confidence in gene therapy at a time when the field was still recovering from setbacks. Now, gene therapy is a fast-growing field, with many publicly traded companies, a handful of approved products and dozens of startups raising record levels of investment from venture investors.

But Bluebird has had a bumpy ride since debuting as a public company in 2013. Shares swung wildly over the years amid various clinical delays and manufacturing setbacks, while competition from newer gene editing technologies dimmed the outlook for some of its treatments. At less than $30 per share, Bluebird’s stock currently trades at levels not recorded for eight years.

The approval of Skysona reflects Bluebird’s up-and-down story. It’s a scientific achievement, making Bluebird the first company with two marketed gene replacement therapies. (The company also successfully developed an genetically engineered cell therapy called Abecma for the blood cancer multiple myeloma. Others have multiple cell therapies approved.) READ MORE

By Ben Fidler


comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach